Sociedad Americana de Hirudoterapia

Thrombin induced tumour growth - pharmacological control

Research article published in Hamostaseologie (2007)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosFarmacología salivalNowak G et al. · Hamostaseologie, 2007

Abstract

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article
Indexed MeSH termsAmino Acid SequenceCell DivisionHirudinsHumansModels, MolecularMolecular Sequence DataNeoplasmsProtein ConformationReceptor, PAR-1Receptors, ThrombinSignal TransductionThrombin

Resumen

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells.

Por qué esto importa para la hirudoterapia

This abstract examines how thrombin modifies tumor cell growth through protease-activated receptors (PAR-1 and PAR-4) and tests PEG-coupled direct thrombin inhibitors as a means of controlling thrombin activity in the tumor microenvironment, reporting significant carcinostatic effects in xenographic tumor models. This work is tangentially relevant to the broader pharmacology of thrombin inhibition. However, the abstract makes no mention of hirudin, leeches, or any leech-derived compounds. The study involves a PEG-coupled inhibitor class, not hirudin or related molecules, so the connection to hirudotherapy or the leech secretome is not established by this abstract.

Citación

Thrombin induced tumour growth - pharmacological control

Nowak G et al. · Hamostaseologie, 2007

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.